Microsoft and Meta's strong earnings reports that eased investor fears of an economic slowdown amid President Trump's tariffs ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Researchers in Dallas want to know if the class of drugs, GIP/GLP-1 receptor agonists, might be a secret weapon in the fight ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their ...

UB researcher Nicole Albanese talks about recent developments, including the end of the shortage of weight-loss drugs and the ...

1st place: £300 Wex Photo Video voucher, plus a framed print of the winning image 2nd place: A one-year subscription to Digital Camera magazine, plus a framed print of the winning image 3rd place: A ...

The F.D.A. ordered compounding for versions of Eli Lilly’s Zepbound to end last month. Small compounders have until April 22 to stop making and selling versions of Novo Nordisk’s Wegovy ...

Eli Lilly and Co.’s Zepbound, for instance, brought in nearly $5 billion in sales in 2024, its first full year on the market. But leading treatments like Zepbound and Novo Nordisk’s Wegovy are ...

Eli Lilly and Co.’s Zepbound, for instance ... patients who don’t want to deal with needles and daily injections. Advertising Lilly researchers expect to see data this year from studies ...

Yo what is up guys, Fabian Rizzo here and this video is about me showing you guys how print on demand works and to show you guys if running ads that are built in to the platform or your choice ...